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Identifying Candidate Mendelian Stroke Genes 
To identify relevant Mendelian stroke genes, MEDLINE and Embase were searched for relevant articles published in English from January 1, 1990 
to June 12, 2018. In consultation with a health sciences librarian, a search strategy was created in four parts: (1) terms specific to the outcome 
including “stroke”, “ictus” and “intracerebral hemorrhage”; (2) terms highlighting the occurrence of the outcome including “prevalence” and 
“penetrance”; (3) terms related to disease inheritance such as “monogenic”, “Mendelian”, and “hereditary”; and (4) terms related to the cause of 
disease such as “mutation” or “variation”. 
 
The search strategy encompassed the following:  
January 1st, 1990 to June 12th, 2018 [only in humans, only English] in Embase, OVID MEDLINE Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946-Present  
exp STROKE/ OR stroke* OR ictus OR ischemi* OR hemorrhag* OR intracerebral adj1 hemorrhage OR infarct* AND exp PREVALENCE/ OR 
prevalen* OR occurrence OR penetran* AND monogenic OR Mendelian OR hereditary OR exp GENES, DOMINANT OR dominant OR exp 
GENES, RECESSIVE OR recessive OR single adj1 gene AND exp MUTATION OR mutation* OR variation OR non-synonymous 
 
Eligible publications were screened for potentially relevant genetic loci and new studies discussing novel loci published after the initial search were 
also included. Only studies that denoted genetic variants in certain individuals were included. The maximum age referenced in articles was limited 
to 70 years old and stroke attributable to antecedent head trauma or sympathomimetic drugs led to article exclusion. Most importantly, only genes 
that were shown to lead to stroke as a prevailing clinical manifestation were analyzed. Genes were excluded if 1) stroke was not a primary feature, 
2) there was an absence of clear evidence of Mendelian inheritance, 3) the gene was encoded in the mitochondrial genome. A total of 39 articles 
were included from 880 unique publications. Overall, 18 candidate genes (Table VI) were found to be directly implicated in the development of 
stroke and followed a Mendelian inheritance pattern. 
 
gnomAD Population Data 
The Genome Aggregation Database (gnomAD) is the largest publicly-available population dataset to date and makes summary-level genetic data 
available for the wider scientific community.1 Research was approved by the Hamilton Integrated Research Ethics Board. gnomAD ethics approval 
is overseen by the Broad Institute’s Office of Research Subject Protection and the Partners Human Research Committee, and informed consent was 
obtained from all participants. Only samples from individuals who were not ascertained for having a neurological condition in a neurological 
case/control study were used in this study (gnomAD v2.1.1 non-neuro subset). The dataset comprised genetic information from 101,635 unrelated 
individuals sequenced by whole-exome sequencing from dozens of international contributing projects. Individuals known to be affected by severe 
pediatric disease as well as their first-degree relatives were removed. 
 
Principal component analysis (PCA) organized gnomAD participants into seven distinct ethnic groups by ancestry: African/African-American 
(AFR), Latino/Admixed American (AMR), Ashkenazi Jewish (ASJ), East Asian (EAS), Finnish European (FIN), Non-Finnish European (NFE), and 
 
2 
South Asian (SAS). A number of unassigned individuals classified as Other (OTH) did not visibly cluster with any of the seven major populations 
and were not analyzed. 
 
Variant Annotation, Filtering and Classification 
A web-based version of ANNOVAR was used to annotate variant mutation effects based on ENSEMBL transcripts.2 Only rare non-synonymous 
mutations within the 18 genes were analyzed in the present study. Non-synonymous mutations included any variants which are predicted to alter the 
primary amino acid sequence of the protein product; missense, inframe insertion/deletion, frameshift, start gain/loss, stop gain/loss, and splice site 
variants were included. In gnomAD these variants were listed as “loss of function (LoF)” and “missense”. Variants with dubious annotation and/or 
quality were removed. Rare variants were defined as those having a minor allele frequency (MAF) <0.001 within the gnomAD v2.1.1 (non-neuro) 
dataset. This MAF threshold was applied within each ethnic subdivision of gnomAD (AFR, AMR, ASJ, EAS, FIN, NFE, SAS) and for each variant 
class. If a variant was common (MAF≥0.001) in a single ethnic group, then it was excluded from analysis. The remaining variants were deemed to 
be globally rare. Several bona fide pathogenic mutations were spiked into MAF calculations after the MAF threshold was established. Two well-
established pathogenic founder NOTCH3 variants with MAF>0.001 were included in the analysis (R544C and R1231C). One well-established 
RNF213 pathogenic founder variant with MAF>0.001 was included (R4810K). These founder mutations were included irrespective of frequency. 
Based on cumulative minor allele frequencies, carrier frequencies were calculated and used to estimate the prevalence of putatively disease-causing 
mutations for each gene. 
 
Definition of Pathogenic Clinical Variants 
Pathogenic clinical variants encompassed three subgroups of mutation types.  
1. Firstly, canonical disease-causing (CDC) mutations were extracted from gnomAD. These variants were directly relevant to clinical cases 
and followed highly stereotypical patterns consistent with known disease pathways. Rare variants were categorized as CDC mutations if 
they strongly resembled reported disease-causing mutations from genetic databases: The Online Mendelian Inheritance of Man compendium 
(OMIM) and/or the National Institutes of Health’s Genetic Home reference (NIH-GHR).  
2. Next, suspected pathogenic variants associated with the gene of interest systematically found in literature or large case series were extracted 
from gnomAD.  
3. Lastly, variants associated with the gene and disorder of interest that were unambiguously classified as pathogenic or likely pathogenic in 
ClinVar were extracted from gnomAD.3 
 
Note: NOTCH3 cysteine-sparing variants, while searchable in gnomAD non-neuro, were excluded from analysis since their pathogenicity is still 
debated.4  
 
Baseline disease prevalence estimates were found by searching the rare disease registry, Orphanet, and clinical presentation was described in the 
National Institutes of Health’s Genetics Home Reference.  
 
Twelve genes (ABCC6, CECR1, COL3A1, COL4A1, COL4A2, COLGALT1, GLA, HTRA1, KRIT1, NOTCH3, RNF213, and TREX1) were found to 
exhibit pathogenic clinical mutations. Only NOTCH3 and COL4A1, however, presented CDC mutations. NOTCH3 mutations that involved a gain 
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or loss of cysteine in one of the 34 epidermal growth factor-like repeat (EGFR) domains (ENSG00000074181) (residues 40-1373) and COL4A1 
glycine-altering variants in the triple-helical domain (ENSG00000187498) (residues 173-1440) were included.5,6 
 
Using CADD to Predict Variant Effect 
CADD v1.4 utilizes in-silico algorithms to predict variant deleteriousness of any non-synonymous mutations based on biochemical characteristics 
and sequence conservation. CADD scores expanded variant inclusion criteria to encompass all rare non-synonymous mutations with PHRED-scaled 
C-scores >20.00 and MAF<0.001. These mutations rank among the top 1% of deleterious variants and are more likely to be implicated in disease 
development. This mutation class lacks the specificity of pathogenic clinical variants but may allow for novel variants associated with disease to be 
determined.7 
 
All Non-Synonymous Variants 
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Table II: CADD-Predicted Deleterious Variant Carrier Frequency (per 1000) Stratified by gnomAD v2.1.1 (non-neuro) Subpopulation 
Ethnicity 
Gene SAS EAS ASJ AFR NFE FIN AMR 
ABCC6 21.94 27.92 5.16 19.82 15.00 5.58 17.59 
APP 8.70 10.32 1.61 11.88 6.34 1.67 7.87 
CCM2 7.06 5.08 1.94 5.84 6.01 1.56 2.49 
CECR1 6.01 2.38 0.64 3.71 3.49 2.16 6.49 
COL3A1 13.07 12.82 1.29 8.59 8.44 1.55 9.92 
COL4A1 12.74 8.23 0.98 12.35 11.42 3.62 12.73 
COL4A2 17.39 18.90 6.40 18.42 17.71 7.52 21.39 
COLGALT1 9.97 10.58 1.94 11.34 9.04 0.91 9.75 
CST3 1.09 0.30 0.78 0.77 0.77 0 1.44 
CTSA 3.46 5.59 0.64 6.43 3.58 2.75 4.00 
GLA 0.42 0.79 0 2.15 1.52 0 0.74 
HTRA1 4.67 4.23 0.64 3.24 4.61 3.20 7.01 
ITM2B 1.21 2.39 0.64 1.98 1.24 0.24 2.20 
KRIT1 6.15 4.77 2.26 6.54 5.24 1.91 4.33 
NOTCH3 27.39 34.64 8.28 32.09 20.67 5.26 24.59 
PDCD10 0.85 0.45 0.32 0.99 0.76 0 0.66 
RNF213 49.96 41.50 8.95 27.71 29.13 8.74 34.61 
TREX1 5.10 6.27 0.32 5.24 3.83 0.84 2.36 








































Gene SAS EAS ASJ AFR NFE FIN AMR 
ABCC6 38.98 47.61 7.19 40.86 31.30 12.80 32.73 
APP 14.93 13.13 1.93 15.62 9.05 2.65 10.95 
CCM2 9.42 8.16 2.38 9.00 7.94 1.80 6.78 
CECR1 13.73 6.41 1.61 9.26 10.40 3.24 14.23 
COL3A1 16.68 20.95 2.03 13.22 11.68 1.55 13.52 
COL4A1 30.00 23.30 2.99 22.88 20.61 4.93 24.12 
COL4A2 37.27 34.28 9.68 28.55 27.40 11.09 36.57 
COLGALT1 14.10 14.31 3.22 18.90 14.15 3.12 15.00 
CST3 5.88 2.25 1.54 2.90 2.09 0.57 3.15 
CTSA 6.09 13.43 2.48 14.51 9.15 3.11 9.64 
GLA 4.30 1.38 0.43 6.11 4.61 0.49 4.11 
HTRA1 6.42 4.90 1.50 5.58 5.73 3.44 8.23 
ITM2B 2.78 5.82 1.29 5.01 2.76 0.60 3.68 
KRIT1 8.96 10.44 2.26 10.49 7.32 4.19 6.56 
NOTCH3 42.58 47.10 10.52 46.99 32.69 8.37 39.14 
PDCD10 1.77 1.34 0.32 2.10 2.75 0 1.38 
RNF213 107.47 107.69 22.92 91.86 78.52 22.00 96.94 
TREX1 9.22 12.39 3.22 10.12 6.95 3.08 6.69 
Total 370.56 374.90 77.51 353.98 285.11 87.03 333.39 
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Table IV: Pathogenic Clinical Variants Associated with CADASIL in gnomAD v2.1.1 (non-neuro)  
Legend: SAS = South Asian, EAS = East Asian, ASJ = Ashkenazi Jewish, AFR = African/African-American, NFE = Non-Finnish European, FIN = 
Finnish European, AMR = Latino/Admixed American, AF = Allele Frequency 
Chromosome Position rsID Reference Alternate Protein Consequence Annotation SAS AF EAS AF ASJ AF AFR AF NFE AF FIN AF AMR AF 
19 15289890 rs199638166 A C p.Cys1222Gly Missense 0 0 0 6.22E-05 2.25E-04 0 0 
19 15289986 rs377099118 G A p.Arg1190Cys Missense 1.63E-04 1.50E-04 0 0 3.37E-05 0 0 
19 15295828 rs532100840 G A p.Arg767Cys Missense 0 4.60E-04 0 0 0 4.02E-04 0 
19 15296215 rs144163298 G A p.Arg717Cys Missense 3.29E-05 1.51E-04 0 1.32E-04 4.65E-05 0 0 
19 15289953 rs772172068 G A p.Arg1201Cys Missense 3.27E-05 7.49E-05 0 0 6.74E-05 0 6.56E-05 
19 15297997 rs754554486 G A p.Arg587Cys Missense 0 2.24E-04 0 0 0 0 1.97E-04 
19 15298024 rs769773673 G A p.Arg578Cys Missense 0 7.47E-05 0 6.20E-05 2.25E-05 0 1.64E-04 
19 15297722 rs760768552 G A p.Arg640Cys Missense 0 2.24E-04 0 6.17E-05 1.12E-05 0 6.55E-05 
19 15298084 rs75068032 G A p.Arg558Cys Missense 0 0 0 0 5.60E-05 0 0 
19 15290208 rs60373464 G A p.Arg1143Cys Missense 0 7.45E-05 0 0 2.23E-05 0 0 
19 15295249 rs776115188 TGGCATCGTG T p.Pro805_Cys807del Inframe Deletion 0 7.46E-05 0 0 0 0 0 
19 15291915 rs775964142 G A p.Arg951Cys Missense 0 7.84E-05 1.68E-04 0 0 0 0 
19 15297737 rs753801611 G A p.Arg635Cys Missense 0 7.45E-05 0 0 0 0 3.28E-05 
19 15289926 rs758961316 G A p.Arg1210Cys Missense 3.27E-05 0 0 0 1.12E-05 0 0 
19 15291029 rs1320508682 A G p.Cys1061Arg Missense 3.27E-05 0 0 0 1.12E-05 0 0 
19 15291810 rs763321998 A G p.Cys986Arg Missense 3.64E-05 0 0 0 1.33E-05 0 0 
19 15291942 rs777577687 C A p.Gly942Cys Missense 0 0 0 0 2.46E-05 0 0 
19 15296182 rs1057519101 G A p.Arg728Cys Missense 0 0 0 0 2.32E-05 0 0 
19 15295135 rs558392935 C T p.Cys846Tyr Missense 0 7.46E-05 0 0 0 0 0 
19 15295804 rs1383763025 A G p.Cys775Arg Missense 0 1.15E-04 0 0 0 0 0 
19 15297937 rs777751303 G A p.Arg607Cys Missense 0 7.46E-05 0 0 0 0 0 
19 15288794 rs1396345163 G C p.Cys1315Trp Missense 0 0 0 0 5.00E-05 0 0 
19 15289641 rs1339695535 C T p.Cys1277Tyr Missense 3.64E-05 0 0 0 0 0 0 
19 15289747 rs769660847 G A p.Arg1242Cys Missense 0 0 0 0 1.13E-05 0 0 
19 15289949 rs754523402 C G p.Cys1202Ser Missense 0 0 0 0 0 0 3.28E-05 
19 15289982 rs1192888680 C G p.Cys1191Ser Missense 0 0 0 0 0 0 3.28E-05 
19 15290279 rs1266914122 C T p.Cys1119Tyr Missense 0 0 0 0 1.12E-05 0 0 
19 15291004 rs1438064001 T C p.Tyr1069Cys Missense 0 0 0 0 0 5.98E-05 0 
19 15291918 rs1378535955 A C p.Cys950Gly Missense 0 0 0 0 0 6.19E-05 0 
19 15291969 rs749778923 A C p.Cys933Gly Missense 0 0 0 0 0 0 3.34E-05 
19 15292508 rs1447534769 A C p.Cys891Gly Missense 0 0 0 0 0 0 0 
19 15292598 rs757098265 C A p.Gly861Cys Missense 0 0 0 0 0 0 4.64E-05 
19 15296177 rs760081167 G T p.Cys729Ter Stop Gained 0 0 1.67E-04 0 0 0 0 
19 15296404 rs1250956327 G A p.Arg680Cys Missense 3.27E-05 0 0 0 0 0 0 
19 15296452 rs1350049644 T A p.Ser664Cys Missense 0 0 0 0 1.12E-05 0 0 
19 15297933 rs778350156 C T p.Cys608Tyr Missense 0 0 0 0 1.13E-05 0 0 
19 15297982 rs764148985 G A p.Arg592Cys Missense 0 0 0 0 1.12E-05 0 0 
19 15298087 rs1317994194 C A p.Gly557Cys Missense 3.27E-05 0 0 0 0 0 0 
19 15298704 rs1202763005 G A p.Arg532Cys Missense 0 0 0 1.18E-04 0 0 0 
19 15299808 rs1325111374 C CA p.Cys457LeufsTer15 Frameshift 0 0 0 0 0 0 3.34E-05 
19 15302831 rs775267348 G A p.Arg207Cys Missense 0 0 0 0 1.13E-05 0 0 
19 15303013 rs1236699193 C T p.Cys146Tyr Missense 0 0 0 0 0 0 3.33E-05 
19 15303053 rs137852642 G A p.Arg133Cys Missense 0 0 0 0 0 6.33E-05 0 
19 15296443 rs376046941 C A p.Gly667Cys Missense 0 0 0 0 0 0 0 
19 15298126 rs201118034 G A p.Arg544Cys Missense 9.81E-05 3.66E-03 0 0 0 0 3.28E-05 




Table V: Cysteine-Sparing Variants Associated with CADASIL in gnomAD v2.1.1 (non-neuro) (MAF<0.001) 
 
Chromosome Position rsID Reference Alternate Protein Consequence Annotation SAS AF EAS AF ASJ AF AFR AF NFE AF FIN AF AMR AF 
19 15308327 rs200595885 G A p.Arg61Trp Missense 6.57E-05 7.56E-05 3.32E-04 1.99E-04 2.55E-04 0 3.30E-05 
19 15302857 rs140914494 G A p.Ala198Val Missense 0 2.25E-04 0 0 5.65E-05 0 0 
19 15302858 rs375682932 C T p.Ala198Thr Missense 0 0 0 0 3.39E-05 5.99E-05 3.28E-05 
19 15299803 rs370186772 C T p.Ala459Thr Missense 0 0 0 0 0 0 0 
19 15272105 rs372833545 C T p.Gly2112Ser Missense 0 3.89E-04 0 0 4.37E-05 0 0 
19 15298793 rs778571943 G A p.Ser502Phe Missense 0 0 0 1.17E-04 1.41E-04 7.40E-05 4.84E-05 
19 15296089 rs1442324683 T A p.Thr759Ser Missense 0 0 0 0 1.14E-05 0 0 
19 15289998 rs1400946198 C G p.Val1186Leu Missense 0 0 0 0 1.12E-05 0 0 
19 15303235 rs1470690834 A G p.Val98Ala Missense 0 0 0 0 1.15E-05 0 0 
19 15289686 rs143684274 C A p.Arg1262Leu Missense 0 0 0 6.61E-05 1.17E-04 6.13E-05 0 
19 15302288 rs769567750 G A p.Thr328Ile Missense 0 0 0 0 1.13E-05 0 0 
19 15299072 rs376728138 T C p.Asn489Ser Missense 7.14E-05 0 0 0 7.39E-05 1.89E-04 4.54E-04 
19 15291825 rs143695196 G A p.His981Tyr Missense 0 0 0 0 9.32E-05 0 1.11E-04 
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Table VI: Genetic Loci Associated with Mendelian Stroke
Gene Genetic Disorder 
Mode of 
Inheritance 
Clinical Manifestation Disease Prevalence 
NOTCH3 CADASIL AD 
Migraine with aura, mood disturbance, depression, 
dementia, epileptic seizures 
1 in 25,000 - 50,000 
HTRA1 CARASIL AR 
Spasticity, dementia, alopecia, gait disturbance, 








Epileptic seizures, headaches, paralysis, 
auditory and visual impairment 





AD Drowsiness, headaches, seizures, vomiting, dementia Unknown 
RNF213 Moyamoya disease Unknown 
New small fragile cerebral vessel networks, 
headaches, chorea 
1 in 9500 - 30,000 
COL3A1 
Vascular Ehlers-Danlos 
Syndrome (Type IV) 
AD 
Hypermobility, hypotonia, highly elastic skin, 
abnormal scar formation 





Cervical and axillary papules, Ocular peau d'orange 
lesions and angioid streaks, hypertension, peripheral 
artery disease, coronary artery disease, gastrointestinal 
bleeding 
1 in 25,000 -100,000 
GLA Fabry disease X-Linked 
Acroparesthesia, hypohidrosis, angiokeratoma, corneal 
opacity, tinnitus, chronic kidney disease, 
cardiomyopathy 





Porencephaly, intracranial aneurysms, migraine with 
aura, retinal arteriolar tortuosities and hemorrhage, 






AD Porencephaly, cataracts Unknown 
CECR1 Deficiency of ADA2 AR 
Livedo reticularis, livedo racemosa, 
hepatosplenomegaly, systemic vasculitis 





AD Visual impairment, dementia, headache Unknown 
CTSA CARASAL AD 
Lower cranial nerve dysfunction (vertigo, dysphagia, 





related small vessel 
diseases 
AR 











































Variant Carrier Frequency 
CADD-Predicted Deleterious  
Variant Carrier Frequency 
Total Non-Synonymous  
Variant Carrier Frequency 
SAS 20.09 197.18 370.56 
EAS 28.35 197.15 374.90 
ASJ 3.25 42.79 77.51 
AFR 7.14 179.08 353.98 
NFE 12.89 148.81 285.11 
FIN 7.67 47.51 87.03 
AMR 11.84 170.18 333.39 
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Genotype Call Rate (%) [SD %] 
 Ethnicity 
Gene AFR AMR ASJ EAS FIN NFE SAS 
ABCC6 93.7 [15.1] 95.9 [12.2] 95.6 [13.3] 96.5 [9.7] 95.6 [15.1] 94.1 [15.1] 96.3 [11.8] 
APP 96.6 [13.9] 98.1 [7.6] 98.3 [6.4] 97.6 [9.3] 95.8 [16.8] 96.8 [11.8] 98.4 [6.2] 
CCM2 96.0 [14.4] 97.9 [7.9] 98.0 [6.4] 97.5 [9.7] 94.8 [18.9] 96.4 [12.3] 98.4 [6.4] 
CECR1 99.9 [0.5] 99.9 [0.1] 99.9 [0.2] 100.0 [0.1] 99.7 [1.2] 99.9 [0.4] 100.0 [0.1] 
COL3A1 97.0 [9.7] 98.0 [6.9] 98.4 [5.2] 98.1 [7.0] 98.8 [4.2] 97.3 [9.3] 98.3 [5.7] 
COL4A1 97.4 [11.4] 98.8 [6.3] 98.8 [4.8] 98.5 [10.3] 98.4 [10.0] 98.2 [8.3] 98.9 [5.4] 
COL4A2 90.2 [11.3] 95.2 [10.2] 96.1 [8.5] 93.4 [8.7] 97.3 [5.0] 94.4 [10.9] 96.2 [8.3] 
COLGALT1 95.6 [15.1] 96.5 [12.1] 97.3 [9.4] 96.6 [13.1] 95.4 [12.6] 95.9 [13.7] 97.4 [9.7] 
CST3 64.6 [35.7] 79.7 [21.7] 83.9 [18.7] 71.3 [29.8] 88.4 [13.0] 72.6 [27.9] 82.4 [19.5] 
CTSA 97.9 [7.3] 99.1 [4.1] 99.0 [3.6] 98.9 [4.3] 98.4 [6.0] 98.5 [5.6] 99.3 [3.3] 
GLA 80.8 [0.5] 79.8 [0.2] 74.7 [0.4] 75.5 [0.1] 72.7 [0.2] 72.0 [0.4] 62.1 [0.6] 
HTRA1 83.3 [33.1] 90.5 [19.8] 92.0 [16.7] 86.1 [29.5] 82.5 [33.2] 86.9 [26.0] 91.7 [17.5] 
ITM2B 89.8 [23.0] 95.2 [11.0] 95.9 [9.3] 92.5 [17.2] 97.3 [5.9] 93.7 [14.4] 95.6 [10.1] 
KRIT1 99.8 [0.4] 99.9 [0.1] 99.9 [0.1] 100.0 [0.0] 99.7 [0.6] 99.8 [0.5] 99.9 [0.1] 
NOTCH3 85.7 [21.5] 91.6 [14.7] 91.7 [13.3] 91.2 [16.2] 88.3 [20.4] 88.0 [18.8] 92.9 [12.5] 
PDCD10 99.8 [0.4] 99.8 [0.2] 99.9 [0.1] 99.9 [0.1] 99.6 [0.6] 99.9 [0.1] 99.9 [0.2] 
RNF213 92.5 [17.8] 95.5 [11.1] 96.3 [9.0] 94.7 [13.2] 89.5 [26.2] 93.4 [15.7] 96.4 [8.9] 
TREX1 99.0 [1.6] 99.9 [0.1] 99.9 [0.3] 99.6 [0.8] 98.7 [3.1] 99.4 [0.9] 100.0 [0.1] 
 









































Table X: Variant Annotations by Gene and Mutation Class in gnomAD v2.1.1 (non-neuro) 
 
Note: Because pathogenic variants were established through literature rather than with bioinformatic criteria, certain variants were included as pathogenic 
but not deleterious according to CADD’s PHRED score. 
 
 
Gene Variant Class 







Missense Splice Acceptor Splice Donor Start Gained Start Lost Stop Gained Stop Lost 
ABCC6 Pathogenic Clinical Variants 95 7 0 0 76 3 1 0 0 8 0 
  CADD-Predicted Deleterious Variants 478 0 0 0 453 0 0 0 0 25 0 
  Non-Synonymous Variants 949 43 6 3 844 10 13 0 0 30 0 
APP Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 267 0 0 0 260 0 0 0 0 7 0 
  Non-Synonymous Variants 372 4 9 5 337 4 4 0 0 9 0 
CCM2 Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 142 0 0 0 140 0 0 0 0 2 0 
  Non-Synonymous Variants 246 3 0 0 235 0 5 0 0 2 1 
CECR1 Pathogenic Clinical Variants 19 2 0 0 15 1 0 0 0 1 0 
  CADD-Predicted Deleterious Variants 124 0 0 0 115 0 0 0 0 9 0 
  Non-Synonymous Variants 296 11 2 0 257 7 4 0 3 12 0 
COL3A1 Pathogenic Clinical Variants 2 0 0 0 2 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 332 0 0 0 330 0 0 0 0 2 0 
  Non-Synonymous Variants 475 2 0 2 466 2 1 0 0 2 0 
COL4A1 Pathogenic Clinical Variants 49 0 0 0 49 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 325 0 0 0 325 0 0 0 0 0 0 
  Non-Synonymous Variants 649 1 2 0 640 3 3 0 0 0 0 
COL4A2 Pathogenic Clinical Variants 2 0 0 0 1 0 0 0 0 1 0 
  CADD-Predicted Deleterious Variants 453 0 0 0 434 0 0 0 0 19 0 
  Non-Synonymous Variants 860 43 6 3 770 12 5 0 2 19 0 
COLGALT1 Pathogenic Clinical Variants 1 0 0 0 1 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 215 0 0 0 206 0 0 0 0 9 0 
  Non-Synonymous Variants 346 17 3 1 308 3 4 0 0 10 0 
CST3 Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 36 0 0 0 35 0 0 0 0 1 0 
  Non-Synonymous Variants 83 4 1 2 70 0 3 0 0 3 0 
CTSA Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 151 0 0 0 140 0 0 0 1 10 0 
  Non-Synonymous Variants 285 12 6 1 247 4 3 0 1 11 0 
GLA Pathogenic Clinical Variants 3 0 0 0 3 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 29 0 0 0 29 0 0 0 0 0 0 
  Non-Synonymous Variants 81 0 0 0 81 0 0 0 0 0 0 
HTRA1 Pathogenic Clinical Variants 11 0 0 0 8 0 0 0 0 3 0 
  CADD-Predicted Deleterious Variants 140 0 0 0 135 0 0 0 0 5 0 
  Non-Synonymous Variants 191 4 0 2 177 1 2 0 0 5 0 
ITM2B Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 69 0 0 0 66 0 0 0 1 2 0 
  Non-Synonymous Variants 110 3 4 2 98 0 0 0 1 2 0 
KRIT1 Pathogenic Clinical Variants 6 1 0 0 0 0 1 0 0 4 0 
  CADD-Predicted Deleterious Variants 201 0 0 0 190 0 0 0 0 10 1 
  Non-Synonymous Variants 316 8 4 0 288 1 3 0 0 11 1 
NOTCH3 Pathogenic Clinical Variants 46 1 1 0 43 0 0 0 0 1 0 
  CADD-Predicted Deleterious Variants 642 0 0 0 631 0 0 0 0 11 0 
  Non-Synonymous Variants 1019 16 1 4 972 7 6 0 0 13 0 
PDCD10 Pathogenic Clinical Variants 0 0 0 0 0 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 39 0 0 0 38 0 0 0 1 0 0 
  Non-Synonymous Variants 74 0 1 0 72 0 0 0 1 0 0 
RNF213 Pathogenic Clinical Variants 1 0 0 0 1 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 1005 0 0 0 935 0 0 0 0 70 0 
  Non-Synonymous Variants 2614 105 23 5 2346 25 24 0 1 83 2 
TREX1 Pathogenic Clinical Variants 1 0 0 0 1 0 0 0 0 0 0 
  CADD-Predicted Deleterious Variants 106 0 0 0 101 2 0 0 2 1 0 









































Gene SAS EAS ASJ AFR NFE FIN AMR 
ABCC6 4.52 8.40 2.19 2.48 5.95 3.46 5.68 
CECR1 1.18 0.43 0.20 0.49 1.48 0.19 1.74 
COL3A1 0 0 0 0.23 0.03 0 0 
COL4A1 0.72 0.65 0.20 2.54 2.18 0.65 1.45 
COL4A2 0.13 0 0 0 0.02 0 0 
COLGALT1 0 0 0 0.12 0 0 0 
GLA 0 0 0 0.15 0.05 0 0 
HTRA1 0.78 0.33 0 0.25 0.65 1.78 0.22 
KRIT1 0.13 0 0 0 0 0 0.23 
NOTCH3 11.78 11.26 0.41 0.87 1.90 1.11 2.69 
RNF213 0.85 5.65 0 0 0 0 0.06 
TREX1 0 0 0 0 0 0 0.12 
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